South Dakota Investment Council Lowers Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

South Dakota Investment Council lessened its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 37.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 9,500 shares of the company's stock after selling 5,800 shares during the quarter. South Dakota Investment Council's holdings in Hims & Hers Health were worth $281,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of HIMS. Vanguard Group Inc. increased its holdings in Hims & Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after purchasing an additional 2,020,722 shares during the period. Farallon Capital Management LLC increased its holdings in Hims & Hers Health by 64,338.5% during the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock worth $202,556,000 after purchasing an additional 8,364,000 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Hims & Hers Health by 29.0% in the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock valued at $168,079,000 after acquiring an additional 1,562,302 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Hims & Hers Health by 192.0% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock valued at $152,436,000 after acquiring an additional 4,145,305 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Hims & Hers Health by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock valued at $104,724,000 after acquiring an additional 40,447 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.

Insiders Place Their Bets

In other news, insider Michael Chi sold 17,102 shares of Hims & Hers Health stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $59.75, for a total value of $1,021,844.50. Following the completion of the sale, the insider owned 278,654 shares of the company's stock, valued at $16,649,576.50. The trade was a 5.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Oluyemi Okupe sold 23,107 shares of Hims & Hers Health stock in a transaction on Monday, June 23rd. The shares were sold at an average price of $47.25, for a total value of $1,091,805.75. Following the completion of the sale, the chief financial officer directly owned 63,222 shares of the company's stock, valued at approximately $2,987,239.50. This represents a 26.77% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 772,518 shares of company stock valued at $41,519,462. Corporate insiders own 13.71% of the company's stock.

Hims & Hers Health Stock Performance

HIMS stock traded down $1.12 during midday trading on Thursday, hitting $56.91. 20,235,866 shares of the stock were exchanged, compared to its average volume of 33,645,477. The stock's 50-day moving average price is $53.31 and its 200-day moving average price is $42.35. The stock has a market cap of $12.74 billion, a price-to-earnings ratio of 82.50, a PEG ratio of 1.84 and a beta of 2.02. Hims & Hers Health, Inc. has a fifty-two week low of $13.47 and a fifty-two week high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.08. The company had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. Hims & Hers Health's revenue was up 110.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.05 earnings per share. Research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Morgan Stanley reiterated an "equal weight" rating and issued a $40.00 price objective on shares of Hims & Hers Health in a report on Wednesday, June 11th. Piper Sandler reaffirmed a "neutral" rating and set a $39.00 price objective (up from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Truist Financial increased their price objective on Hims & Hers Health from $45.00 to $48.00 and gave the stock a "hold" rating in a research report on Thursday, July 17th. TD Cowen cut Hims & Hers Health from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $44.00 to $30.00 in a research report on Tuesday, April 29th. Finally, Wall Street Zen raised Hims & Hers Health from a "hold" rating to a "buy" rating in a research report on Sunday. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, Hims & Hers Health has an average rating of "Hold" and an average target price of $39.83.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.